Datapoint: Skyrizi Scores Crohn’s Disease Nod

The FDA last week approved AbbVie’s Skyrizi for the treatment of moderately to severely active Crohn’s disease. It will be the first IL-23 inhibitor in the Crohn’s market basket. Skyrizi was first approved in April 2019 as a treatment for severe plaque psoriasis, an indication for which it currently holds covered or better status for 98% of all insured lives under the pharmacy benefit. About 38% of insured lives have preferred access to Skyrizi, largely with utilization management restrictions applied.

SOURCE: MMIT Analytics, as of 6/22/22

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 2

Datapoint: Blue Shield of California Launches Virtual-First Plan

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 1

Datapoint: FDA Approves Lilly’s Jaypirca in Blood Cancer

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
January 31

Datapoint: Independence Blue Cross to Launch Advanced Network for Gene Therapies

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today